Table IV.

Original criteria of response evaluation in studies available for comparison of therapeutic response.

Author, year	Original criteria of response evaluation	Ref.
Chamberlain et al, 1998	Cytological criteria: CR, 2 consecutive negative CSF (ventricular and lumbar sampling) cytological examinations at least 1 week apart and sustained for at least 1 month on a regimen of stable or decreasing steroid dosage; PR, conversion from positive to suspicious on 2 consecutive CSF (ventricular and lumbar sampling) cytological examinations at least 1 week apart and sustained for at least 1 month on a regimen of stable or decreasing steroid dosage; PD, conversion from negative 2 consecutive examinations to positive, or 2 consecutive positive or suspicious cytological findings. Clinical criteria: CR, resolution of all neurologic signs; PR, incomplete resolution of neurologic signs; SD, no change in clinical signs; PD, worsening of preexisting or new neurologic signs. Neuroradiographic criteria: CR, resolution of all neuroradiographic signs; PR, incomplete resolution of neuroradiographic signs; SD, no change in neuroradiographic signs; PD, worsening of preexisting or new neuroradiographic signs.	(7)
Gwak et al, 2013	Post-treatment ICPs were measured 3 days after cessation of the VLP (i.e. day 7), to avoid the immediate effect of VLP (drainage) on the CSF flow. The other pretreatment symptoms and signs were checked 10 days after completion of the therapy (day 14).	(20)
Nakagawa et al, 1999	Cytological criteria: CR, negative cytology and normal cell counts and tumor marker levels (cell count ≤10/mm3 and 50 mg/dl protein) in both ventricular and spinal CSF; PR, ≥50% reduction in either ventricular or spinal CSF malignant cell count; SD, failure to fulfill criteria for either a response or progressive disease; PD, positive cytology in either ventricular or spinal CSF.	(21)
Nakagawa et al, 1996	Once a week, before and after perfusion therapy, routine and cytological examination of the CSF was performed. Clinical criteria: Good, CSF findings were negative, in association with a moderate to marked improvement of neurological deficits and the ability to walk unassisted; moderate, improvement of both CSF parameters and neurological deficits, regardless of the degree of change; minor, improvement of either the CSF parameters or the neurological deficits; none, no improvement of either their neurological deficits or CSF parameters.	(22)
Lee et al, 2013	No specific evaluation, just mentioned ‘ITC was administered to 109 patients (73.2%), and the median number of ITC administrations was 9 (range, 1–27); only 15 patients achieved cytologically negative conversion’ in the text.	(1)
Gwak et al, 2013	Changes of ICP; other LM-related symptoms were evaluated tentatively as normalized, improved, stationary, and worsen based on patients' subjective statements and a physician's description retrieved from the medical records; cytological criteria are the same as Chamberlain et al in Ref. 6.	(23)
Park et al, 2012	The response of LM to ITC was evaluated by cytological findings of the CSF. An objective systemic response to systemic chemotherapy was assessed by the Response Evaluation Criteria In Solid Tumors.	(24)

Ref., reference; CR, complete response; CSF, cerebrospinal fluid; PR, partial response; PD, progressive disease; SD, stable disease; ICP, intracranial pressure; VLP, ventriculolumbar perfusion; ITC, intrathecal chemotherapy; LM, leptomeningeal metastasis.